$MRNS
MARINUS PHARMACEUTICALS, INC. Stock $mrns

$mrns Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000155837022008577 Filed on May 12, 2022

Income Statement

Concept	2022 Q1	2021 Q4	2021 Q1
Revenue	$14.19M	$1.520M	$1.806M
YoY Change	685.49%	-1.94%
Cost Of Revenue	$1.169M
YoY Change
Gross Profit	$13.02M
YoY Change
Gross Profit Margin	91.76%
Selling, General & Admin	$11.74M	$10.62M	$10.38M
YoY Change	13.07%	76.74%	169.61%
% of Gross Profit	90.17%
Research & Development	$17.99M	$18.01M	$18.59M
YoY Change	-3.23%	38.14%	23.91%
% of Gross Profit	138.21%
Depreciation & Amortization	$85.00K	$93.00K	$85.00K
YoY Change	0.0%	3.33%	1.19%
% of Gross Profit	0.65%
Operating Expenses	$17.99M	$28.64M	$18.59M
YoY Change	-3.23%	50.32%	23.91%
Operating Profit	-$16.71M		-$27.16M
YoY Change	-38.47%		44.06%
Interest Expense	$1.692M	-$1.530M	$20.00K
YoY Change	8360.0%	-3925.0%	-90.91%
% of Operating Profit
Other Income/Expense, Net	-$970.0K	$541.0K	-$4.000K
YoY Change	24150.0%	-5510.0%	-90.0%
Pretax Income	-$19.36M	-$28.31M	-$27.14M
YoY Change	-28.66%	62.02%	45.37%
Income Tax
% Of Pretax Income
Net Earnings	-$19.36M	-$28.31M	-$27.14M
YoY Change	-28.67%	62.02%	45.36%
Net Earnings / Revenue	-136.48%	-1862.17%	-1502.82%
Basic Earnings Per Share	-$0.52		-$0.74
Diluted Earnings Per Share	-$0.52	-$769.4K	-$0.74
COMMON SHARES
Basic Shares Outstanding	36.89M	36.77M	36.60M
Diluted Shares Outstanding	36.89M		36.60M

Balance Sheet

Concept	2022 Q1	2021 Q4	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$126.3M	$122.9M	$123.5M
YoY Change	2.28%	-12.2%	58.74%
Cash & Equivalents	$126.3M	$122.9M	$123.5M
Short-Term Investments		$0.00	$0.00
Other Short-Term Assets	$6.263M	$5.565M	$3.700M
YoY Change	69.27%	20.98%	68.18%
Inventory		$0.00
Prepaid Expenses
Receivables	$2.489M	$2.629M	$2.700M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$135.1M	$131.7M	$129.8M
YoY Change	4.06%	-9.97%	62.25%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.989M	$2.499M	$1.894M
YoY Change	57.81%	28.48%	-56.95%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.750M	$2.663M	$2.167M
YoY Change	26.9%	18.36%	983.5%
Total Long-Term Assets	$5.739M	$5.162M	$4.061M
YoY Change	41.32%	23.05%	-11.72%
TOTAL ASSETS
Total Short-Term Assets	$135.1M	$131.7M	$129.8M
Total Long-Term Assets	$5.739M	$5.162M	$4.061M
Total Assets	$140.8M	$136.8M	$133.9M
YoY Change	5.19%	-9.05%	58.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.671M	$3.126M	$5.167M
YoY Change	-9.6%	41.38%	84.54%
Accrued Expenses	$14.87M	$16.21M	$10.95M
YoY Change	35.7%	90.27%	46.05%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$19.54M	$40.57M	$16.12M
YoY Change	21.18%	278.1%	56.51%
LONG-TERM LIABILITIES
Long-Term Debt	$69.93M	$40.81M	$0.00
YoY Change
Other Long-Term Liabilities	$10.94M	$1.979M	$2.400M
YoY Change	355.92%	-20.84%	-17.24%
Total Long-Term Liabilities	$80.87M	$42.79M	$2.400M
YoY Change	3269.54%	1611.52%	-17.24%
TOTAL LIABILITIES
Total Short-Term Liabilities	$19.54M	$40.57M	$16.12M
Total Long-Term Liabilities	$80.87M	$42.79M	$2.400M
Total Liabilities	$100.4M	$83.35M	$18.53M
YoY Change	442.0%	528.47%	40.34%
SHAREHOLDERS EQUITY
Retained Earnings	-$430.1M	-$410.7M	-$339.1M
YoY Change	26.84%	31.67%
Common Stock	$37.00K	$37.00K	$37.00K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares	$7.307K	$7.307K	$7.307K
Shareholders Equity	$40.41M	$53.49M	$115.3M
YoY Change
Total Liabilities & Shareholders Equity	$140.8M	$136.8M	$133.9M
YoY Change	5.19%	-9.05%	58.23%

Cashflow Statement

Concept	2022 Q1	2021 Q4	2021 Q1
OPERATING ACTIVITIES
Net Income	-$19.36M	-$28.31M	-$27.14M
YoY Change	-28.67%	62.02%	45.36%
Depreciation, Depletion And Amortization	$85.00K	$93.00K	$85.00K
YoY Change	0.0%	3.33%	1.19%
Cash From Operating Activities	-$27.66M	-$21.75M	-$16.18M
YoY Change	70.97%	32.62%	15.23%
INVESTING ACTIVITIES
Capital Expenditures	-$86.00K	-$721.0K	-$30.00K
YoY Change	186.67%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$1.070M
YoY Change		-100.0%	-115.97%
Cash From Investing Activities	-$86.00K	-$721.0K	$1.042M
YoY Change	-108.25%	-129.07%	-115.56%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	31.13M	297.0K	96.00K
YoY Change	32330.21%	-99.54%	-17.95%
NET CHANGE
Cash From Operating Activities	-27.66M	-21.75M	-16.18M
Cash From Investing Activities	-86.00K	-721.0K	1.042M
Cash From Financing Activities	31.13M	297.0K	96.00K
Net Change In Cash	3.392M	-22.17M	-15.04M
YoY Change	-122.56%	-143.33%	-27.07%
FREE CASH FLOW
Cash From Operating Activities	-$27.66M	-$21.75M	-$16.18M
Capital Expenditures	-$86.00K	-$721.0K	-$30.00K
Free Cash Flow	-$27.57M	-$21.03M	-$16.15M
YoY Change	70.76%	28.23%	15.02%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36890568
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36599701
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001267813
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	37140406
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	126319000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	122927000
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2022Q1	us-gaap	Treasury Stock Value TreasuryStockValue
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.52
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.74
CY2022Q1	us-gaap	Operating Lease Liability Statement Of Financial Position Extensible List OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2021-01-31#OtherAccruedLiabilitiesNoncurrent
CY2021Q4	us-gaap	Operating Lease Liability Statement Of Financial Position Extensible List OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2021-01-31#OtherAccruedLiabilitiesNoncurrent
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-36576
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	MARINUS PHARMACEUTICALS, INC.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-0198082
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	5 Radnor Corporate Center, Suite 500
CY2022Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	100 Matsonford Rd
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Radnor
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	19087
CY2022Q1	dei	City Area Code CityAreaCode	484
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	801-4670
CY2022Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2022Q1	dei	Trading Symbol TradingSymbol	MRNS
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2489000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2629000
CY2021Q4	mrns	Contract With Customer Asset Liability Net ContractWithCustomerAssetLiabilityNet	557000
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6263000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5565000
CY2022Q1	us-gaap	Assets Current AssetsCurrent	135071000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	131678000
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2989000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2499000
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2750000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2663000
CY2022Q1	us-gaap	Assets Assets	140810000
CY2021Q4	us-gaap	Assets Assets	136840000
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	4671000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3126000
CY2021Q4	mrns	Upfront Payment Refund Liability UpfrontPaymentRefundLiability	21233000
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14865000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	16207000
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	19536000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	40566000
CY2022Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	69927000
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	40809000
CY2022Q1	mrns	Contract With Customer Contract Liability Net Of Contract Asset ContractWithCustomerContractLiabilityNetOfContractAsset	9113000
CY2022Q1	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	1829000
CY2021Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	1979000
CY2022Q1	us-gaap	Liabilities Liabilities	100405000
CY2021Q4	us-gaap	Liabilities Liabilities	83354000
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	4302000
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	4302000
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37145981
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37138674
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36797561
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36790254
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	37000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	37000
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	466132000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	459852000
CY2022Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	7307
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	7307
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-430066000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-410705000
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	40405000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	53486000
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	140810000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	136840000
CY2022Q1	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	1513000
CY2021Q1	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	1806000
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12673000
CY2022Q1	us-gaap	Revenues Revenues	14186000
CY2021Q1	us-gaap	Revenues Revenues	1806000
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17991000
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18591000
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11737000
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10376000
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1169000
CY2021Q1	mrns	Non Cash Operating Lease Expense Operating Activities NonCashOperatingLeaseExpenseOperatingActivities	73000
CY2022Q1	mrns	Interest Expense Income On Lease Liabilities InterestExpenseIncomeOnLeaseLiabilities	69000
CY2021Q1	mrns	Interest Expense Income On Lease Liabilities InterestExpenseIncomeOnLeaseLiabilities	82000
CY2022Q1	mrns	Fixed Assets Written Off FixedAssetsWrittenOff	61000
CY2022Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1168000
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-930000
CY2022Q1	mrns	Increase Decrease In Contract With Customer Refund Liability IncreaseDecreaseInContractWithCustomerRefundLiability	-22163000
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-10045000
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1072000
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-366000
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-783000
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	30897000
CY2021Q1	us-gaap	Costs And Expenses CostsAndExpenses	28967000
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-16711000
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-27161000
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	12000
CY2021Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	24000
CY2022Q1	us-gaap	Interest Expense InterestExpense	1692000
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-970000
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-19361000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-27141000
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19361000
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-27141000
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.52
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.74
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36890568
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36599701
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-19361000
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-27141000
CY2022Q1	us-gaap	Depreciation Depreciation	85000
CY2021Q1	us-gaap	Depreciation Depreciation	85000
CY2022Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	282000
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3379000
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5035000
CY2022Q1	mrns	Increase Decrease Amortization Of Net Contract Asset Liability IncreaseDecreaseAmortizationOfNetContractAssetLiability	375000
CY2022Q1	mrns	Non Cash Operating Lease Expense Operating Activities NonCashOperatingLeaseExpenseOperatingActivities	80000
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	5325000
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27655000
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16175000
CY2021Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	1474000
CY2021Q1	mrns	Payments For Deposit And Property And Equipment PaymentsForDepositAndPropertyAndEquipment	404000
CY2022Q1	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	86000
CY2021Q1	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	28000
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-86000
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1042000
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1733000
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	244000
CY2022Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	29400000
CY2021Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	148000
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	31133000
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	96000
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3392000
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-15037000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	122927000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	138509000
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	126319000
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	123472000
CY2022Q1	mrns	Contractual Exit Fee Included In Notes Payable ContractualExitFeeIncludedInNotesPayable	563000
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	205000
CY2022Q1	mrns	Property And Equipment In Deposits Placed In Service PropertyAndEquipmentInDepositsPlacedInService	337000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	137199000
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5035000
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	244000
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	3000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-27141000
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	115334000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	53486000
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3379000
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1733000
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1168000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-19361000
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	40405000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-19400000
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-430100000
CY2022Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	75000000.0
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from such estimates.</p>
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3360000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5830000
CY2022Q1	mrns	Clinical Trials And Drug Development Current ClinicalTrialsAndDrugDevelopmentCurrent	8765000
CY2021Q4	mrns	Clinical Trials And Drug Development Current ClinicalTrialsAndDrugDevelopmentCurrent	8217000
CY2022Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1431000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1311000
CY2022Q1	mrns	Debt Issuance Costs And Commitment Fees DebtIssuanceCostsAndCommitmentFees	630000
CY2022Q1	mrns	Lease Liability Short Term LeaseLiabilityShortTerm	575000
CY2021Q4	mrns	Lease Liability Short Term LeaseLiabilityShortTerm	556000
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	104000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	293000
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14865000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	16207000
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7110694
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5409378
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3078000
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4980000
CY2022Q1	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	915000
CY2022Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P78M
CY2022Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P60M
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P42M
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1600000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1700000
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2400000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2500000
CY2022	us-gaap	Lease Cost LeaseCost	100000
CY2022Q1	us-gaap	Lease Cost LeaseCost	200000
CY2022Q1	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.110
CY2022Q1	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0
CY2021	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0
CY2022Q1	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	6626000
CY2022Q1	mrns	Contract With Customer Contract Liability Net Of Contract Asset ContractWithCustomerContractLiabilityNetOfContractAsset	9113000
CY2021Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	7181000
CY2021Q4	mrns	Contract With Customer Asset Liability Net ContractWithCustomerAssetLiabilityNet	557000
CY2022Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	15739000
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	609000
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	823000
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	840000
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	642000
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2914000
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	510000
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2404000
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	575000
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1829000
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2404000
CY2022Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	75000000
CY2022Q1	mrns	Contractual Term Loan Exit Fees ContractualTermLoanExitFees	1500000
CY2022Q1	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	6573000
CY2022Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	69927000
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	11250000
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	15000000
CY2022Q1	mrns	Long Term Debt Maturities Repayments Of Principal In Year Four And Thereafter LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter	48750000
CY2022Q1	us-gaap	Long Term Debt LongTermDebt	75000000
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	6624000

Files In Submission

Name	View Source	Status
0001558370-22-008577-index-headers.html	Edgar Link	pending
0001558370-22-008577-index.html	Edgar Link	pending
0001558370-22-008577.txt	Edgar Link	pending
0001558370-22-008577-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mrns-20220331.xsd	Edgar Link	pending
mrns-20220331x10q.htm	Edgar Link	pending
mrns-20220331x10q004.jpg	Edgar Link	pending
mrns-20220331x10q007.jpg	Edgar Link	pending
mrns-20220331x10q_htm.xml	Edgar Link	completed
mrns-20220331xex31d1.htm	Edgar Link	pending
mrns-20220331xex31d2.htm	Edgar Link	pending
mrns-20220331xex32d1.htm	Edgar Link	pending
mrns-20220331xex3d8.htm	Edgar Link	pending
mrns-20220331_cal.xml	Edgar Link	unprocessable
mrns-20220331_def.xml	Edgar Link	unprocessable
mrns-20220331_lab.xml	Edgar Link	unprocessable
mrns-20220331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MRNS
MARINUS PHARMACEUTICALS, INC. Stock $mrns

2022 Q1 Form 10-Q Financial Statement

#000155837022008577 Filed on May 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRNS MARINUS PHARMACEUTICALS, INC. Stock $mrns

2022 Q1 Form 10-Q Financial Statement

#000155837022008577 Filed on May 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRNS
MARINUS PHARMACEUTICALS, INC. Stock $mrns